799 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Keebeck Wealth Management

Posted by Stanley Muller on Aug 23rd, 2026

Keebeck Wealth Management bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) during the second quarter, Holdings Channel reports. The institutional investor bought 799 shares of the medical research company’s stock, valued at approximately $401,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Elyxium Wealth LLC lifted its position in Thermo Fisher Scientific by 1.9% in the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock worth $613,000 after buying an additional 20 shares in the last quarter. Revolve Wealth Partners LLC increased its position in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. raised its stake in shares of Thermo Fisher Scientific by 0.7% during the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock worth $1,436,000 after purchasing an additional 20 shares in the last quarter. Canandaigua National Trust Co of Florida lifted its holdings in shares of Thermo Fisher Scientific by 3.0% during the 4th quarter. Canandaigua National Trust Co of Florida now owns 765 shares of the medical research company’s stock valued at $443,000 after buying an additional 22 shares during the last quarter. Finally, Princeton Capital Management LLC increased its holdings in Thermo Fisher Scientific by 2.4% in the fourth quarter. Princeton Capital Management LLC now owns 922 shares of the medical research company’s stock worth $534,000 after buying an additional 22 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $629.02 on Friday. The business has a 50 day simple moving average of $542.53 and a 200 day simple moving average of $509.70. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company has a market capitalization of $232.58 billion, a PE ratio of 33.84, a price-to-earnings-growth ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at $12,596,400. This trade represents a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 63,493 shares of company stock valued at $37,657,681. 0.33% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on TMO shares. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research note on Monday, July 6th. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

Check Out Our Latest Research Report on TMO

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.